AUSTIN, Texas, June 14, 2024 /PRNewswire/ — Mindbloom, the leading provider of psychedelic therapy, announced today the findings of the largest peer-reviewed study in the history of ketamine therapy and psychedelic medicine. The study was published in the Journal of Affective Disorders, and was authored by psychiatrists and researchers from Johns Hopkins University School of Medicine, NYU School of Medicine, the Institute for Psycholinguistics and Digital Health, and Mindbloom.
- Largest study: The study reviewed data from 11,441 Mindbloom clients, making it the most comprehensive examination of ketamine therapy to date
- Effectiveness: 62% of clients reported clinically-significant improvements in depression or anxiety, with 28% achieving remission
- Rapid results: Significant symptom improvements were found after only four sessions
- Safety: Fewer than 5% of clients reported adverse effects
- Benefits of continued treatment: 84% of clients who experienced significant improvements in an initial round of treatment maintained improvements or recovered in a second round
“Millions of Americans are suffering from mental illness, and haven’t been helped by traditional treatments,” said co-author and Mindbloom Medical Director Dr. Leonardo Vando. “This study confirms that at-home ketamine therapy can be an effective and fast-acting treatment for depression and anxiety, and shows why psychedelic therapy is going to be a first-line treatment in the next few years.”
The authors noted that the extensive support offered through Mindbloom – including 1:1 coaching, therapeutic content, and group integration – drives the effectiveness and safety of the treatment. In addition, Mindbloom’s at-home ketamine therapy programs overcome barriers like cost, provider availability, and stigma that prevent people from receiving effective mental health care.
“Mindboom’s programs make ketamine therapy accessible and affordable, allowing people to heal from the comfort of home,” said Mindbloom’s Founder and CEO Dylan Beynon. “People have questioned whether ketamine therapy could be delivered safely and effectively at home through telehealth – this study answers that question with an emphatic ‘yes.'”
This is the second peer-reviewed study of Mindbloom’s clinical outcomes. This study corroborates the findings of Mindbloom’s first study over a 10X larger sample, and provides new analysis demonstrating the benefits of continuing ketamine therapy beyond the initial course of treatment.
The study also used artificial intelligence (AI) and machine learning tools to identify factors that predict whether a client will respond to treatment, providing clinicians with additional information to support their clients.
About Mindbloom:
Mindbloom is the largest provider of psychedelic medicine, with psychiatric clinicians facilitating more than 275,000 at-home ketamine therapy sessions per year in 36 states. Mindbloom offers ketamine therapy for a range of mental health issues, with programs that combine evidence-based medicine with coaching, content, and community. For more information, visit www.mindbloom.com.